乳腺癌中GFRA1表达临床意义的生物信息学分析  

Bioinformatic analysis and the clinical significance of GFRA1 expression in breast cancer

作　　者：谢萍芳[1] 赵东怡 周美容 张丹华[1] 邹琼燕[1] 周恩相[1] 易文君[1] 李伦[1] Pingfang Xie;Dongyi Zhao;Meirong Zhou;Danhua Zhang;Qiongyan Zou;Enxiang Zhou;Wenjun Yi;Lun Li(Department of Breast and Thyroid,Department of General Surgery,The Second Xiangya Hospital,Central South University,Changsha 410000,China)

机构地区：[1]中南大学湘雅二医院普外乳甲专科,长沙市410000

出　　处：《中国肿瘤临床》2018年第15期769-773,共5页Chinese Journal of Clinical Oncology

摘　　要：目的:通过生物信息学的方法分析胶质细胞系源性神经营养因子受体1(glial cell line derived neurotrophic factorα1,GFRA1)在乳腺癌组织中表达情况及其临床意义。方法:全面检索GEO、TCGA、Oncomine、Kmplot数据库分析GFRA1在乳腺癌中表达情况,分析其预测化疗、内分泌治疗疗效和预后的价值。结果:GFRA1在不同类型乳腺癌组织中高表达(P<0.05),与ER(r=0.66)、PR(r=0.22)表达水平呈正相关,与HER-2(r=-0.09)、Ki-67(r=-0.12)表达水平呈负相关。GFRA1低表达乳腺癌患者对他莫昔芬和多柔比星易产生耐药。GFRA1表达水平与乳腺癌患者预后显著相关(P<0.05),GFRA1高表达患者总生存率、无复发生存率高于低表达患者。结论:GFRA1在乳腺癌组织中高表达,低表达乳腺癌患者对他莫昔芬和多柔比星耐药,且预后较差。Objective： To analyze the expression of GFRA1 in breast cancer tissues and its predictive value for therapy and prognosis by biomformatics. Methods： The GEO, TCGA, Oncomine and Kmplot databases were retrieved to include relevant studies that related to the expression of GFRA1 in breast cancer, and analyze its predictive value in chemotherapy, endocrine therapy, and prognosis. Results：GFRA1 was highly expressed in different types of breast cancer tissues（P0.05）, positively correlated to ER and PR expression（r=0.66 and r=0.22, respectively）, and negatively correlated with HER-2 and Ki-67 expression（r=-0.09 and r=-0.12, respectively）. Patients with low GFRA1 expression were susceptible to tamoxifen and doxorubicin resistance. GFRA1 expression significantly correlated with the prognosis of breast cancer patients（P0.05）, and patients with higher expression of GFRA1 survived longer than those with low expression（hazard ratio1）. Conclusions： GFRA1 is highly expressed in breast cancer tissues, and patients with low expression are resistant to tamoxifen and doxorubicin, and their prognosis is poor.

关 键 词：生物信息学 GFRA1 乳腺癌 耐药 预后 

分 类 号：R737.9[医药卫生—肿瘤]